BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34240508)

  • 1. Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas.
    Hiroshima K; Wu D; Koh E; Sekine Y; Ozaki D; Yusa T; Nakazawa T; Tsuji S; Miyagi Y; Walts AE; Marchevsky AM; Husain AN; Imai K
    Pathol Int; 2021 Sep; 71(9):604-613. PubMed ID: 34240508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
    Naso JR; Tsuji S; Churg A
    Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases.
    Churg A; Naso JR
    Histopathology; 2023 Feb; 82(3):385-392. PubMed ID: 36008876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uroplakin-IIIb as a novel immunohistochemical marker for mesothelioma.
    van Pel DM; Cheung S; Ionescu DN; Churg A
    Hum Pathol; 2023 Nov; 141():64-68. PubMed ID: 37776956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.
    Hiroshima K; Wu D; Hamakawa S; Tsuruoka S; Ozaki D; Orikasa H; Hasegawa M; Koh E; Sekine Y; Yonemori Y; Nabeshima K; Tsuji S; Miyagi Y; Imai K
    Diagn Cytopathol; 2021 May; 49(5):622-632. PubMed ID: 32441895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma.
    Naso JR; Cheung S; Ionescu DN; Churg A
    Am J Surg Pathol; 2021 Sep; 45(9):1245-1251. PubMed ID: 33782226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.
    Padgett DM; Cathro HP; Wick MR; Mills SE
    Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
    Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
    Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.
    Tsuji S; Washimi K; Kageyama T; Yamashita M; Yoshihara M; Matsuura R; Yokose T; Kameda Y; Hayashi H; Morohoshi T; Tsuura Y; Yusa T; Sato T; Togayachi A; Narimatsu H; Nagasaki T; Nakamoto K; Moriwaki Y; Misawa H; Hiroshima K; Miyagi Y; Imai K
    Sci Rep; 2017 Mar; 7():45768. PubMed ID: 28361969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations.
    Ren HZ; Cheung S; Churg A
    Hum Pathol; 2020 Nov; 105():31-36. PubMed ID: 32916162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations.
    Salisbury T; Churg A
    Virchows Arch; 2021 Nov; 479(5):1047-1050. PubMed ID: 33721119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia.
    Chapel DB; Hirsch MS
    Am J Surg Pathol; 2022 Feb; 46(2):213-219. PubMed ID: 34411029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
    Naso JR; Churg A
    Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.
    Nakagiri T; Amatya VJ; Kushitani K; Kambara T; Aoe K; Endo I; Miyata Y; Okada M; Takeshima Y
    Am J Surg Pathol; 2024 Feb; 48(2):140-149. PubMed ID: 37899530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
    Müller AM; Franke FE; Müller KM
    Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
    Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
    Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas.
    Bernardi L; Bizzarro T; Pironi F; Szymczuk S; Buda R; Fabbri E; Di Claudio G; Rossi G
    Cancer Cytopathol; 2021 Apr; 129(4):275-282. PubMed ID: 33045147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.